Topic Hub

Flibanserin — Regulatory History

5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.

5articles

39keywords mapped

2026-05-26latest review

Explore

Flibanserin — Regulatory History library

Showing 5 of 5 clinical reviews.

Clinical Reviews2026-05-26

Addyi (Flibanserin) Compounding Legal Status: FDA Rules, REMS, and 503A/503B Limits

Is compounding flibanserin legal? A clinical breakdown of Addyi's FDA approval history, REMS requirements, 503A and 503B pharmacy rules, and what prescribers and patients need to know about compounded flibanserin access.

Read clinical review

Safety2026-05-26

Addyi (Flibanserin) FAERS Safety Signals: Post-Market Surveillance Data and Label Updates

A clinical review of flibanserin (Addyi) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including syncope, hypotension, and CNS depression data from post-market surveillance.

Read clinical review

Access2026-05-27

Addyi (Flibanserin) Legal and Patent Challenges: FDA History, REMS, and Generic Access

A clinical review of Addyi's FDA approval history, patent disputes, REMS modifications, and the legal battles that shaped flibanserin access for women with HSDD.

Read clinical review

Comparisons2026-05-26

Addyi (Flibanserin): EMA vs FDA Regulatory Approaches Compared

A clinical comparison of how the FDA approved Addyi (flibanserin) for HSDD while the EMA declined authorization, including trial data, safety requirements, and post-market changes.

Read clinical review

Clinical Reviews2026-05-25

Addyi Label Updates 2020 to 2026: A Complete Regulatory Timeline

Comprehensive timeline of FDA label changes for Addyi (flibanserin) from 2020 through 2026, including the alcohol contraindication removal, REMS modifications, and post-market safety data.

Read clinical review